HSulf-1 Modulates HGF-mediated Tumor Cell Invasion and Signaling in Head and Neck Squamous Carcinoma
Overview
Authors
Affiliations
Recently, we cloned a novel sulfatase domain-containing downregulated gene, HSulf-1, which modulates heparin-binding growth factor signaling in ovarian cancer. Based on the pilot data showing the loss of HSulf-1 in head and neck squamous cell carcinoma cell lines (SCCHN), we sought to employ SCCHN as a model to define the role of HSulf-1 in the molecular regulation of tumorigenicity. Three SCCHN lines (012SCC, WMMSCC, and 015SCC) had no detectable HSulf-1 mRNA. Clonal lines of HSulf-1-expressing 012SCC attenuated the activation of ERK/mitogen-activated protein kinase (MAPK) signaling mediated by fibroblast growth factor (FGF-2) and both ERK/MAPK and Akt signaling mediated by hepatocyte growth factor (HGF). Consistent with this downregulation, phosphorylation of HGF receptor, c-Met, which is frequently overexpressed in SCCHN, was also attenuated in HSulf-1 clonal 012SCC cell lines. HGF markedly enhanced the motility and migration of vector-transfected cells in a transwell invasion chamber. However, HGF-mediated motility and invasion was attenuated in HSulf-1 clonal 012SCC cell lines. In addition, transfected cells displayed significant growth inhibition concomitant with a decrease in mitogenicity, as measured by thymidine incorporation and increased sensitivity to staurosporine- and cisplatin-induced apoptosis. These data suggest that HSulf-1 normally functions as a negative regulator in cell growth and loss of HSulf-1 in SCCHN potentiates growth factor signaling, enhances motility, invasiveness and inhibits stress-induced apoptosis, with a resulting increase in tumorigenicity.
Han M, Zhu H, Chen X, Luo X Am J Cancer Res. 2024; 14(2):897-916.
PMID: 38455409 PMC: 10915330.
Fang X, Chen D, Yang X, Cao X, Cheng Q, Liu K Cell Death Discov. 2024; 10(1):111.
PMID: 38438372 PMC: 10912303. DOI: 10.1038/s41420-024-01882-y.
SULF1 Activates the VEGFR2/PI3K/AKT Pathway to Promote the Development of Cervical Cancer.
Li J, Wang X, Li Z, Li M, Zheng X, Zheng D Curr Cancer Drug Targets. 2023; 24(8):820-834.
PMID: 37539927 DOI: 10.2174/1568009623666230804161607.
Jiang L, Xu F, Li C, Liu T, Zhao Q, Liu Y Cancer Med. 2023; 12(9):10738-10754.
PMID: 36880364 PMC: 10225225. DOI: 10.1002/cam4.5759.
EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression.
Lin Z, Chung C, Liu Y, Chang C, Liu H, Liang Y Elife. 2023; 12.
PMID: 36622753 PMC: 9829410. DOI: 10.7554/eLife.79432.